[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338261-105":59,"doc-detail-338261-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-non-v600-mutations-in-braf-a-single-institution-retrospective-analysis-and-review-of-the-literature","Targeting Non-V600 Mutations in BRAF - A Single Institution Retrospective Analysis and Review of the Literature","","Background and objective: While BRAF V600 mutations have established treatments, about 10% are non-V600 and lack a standardized regimen. Methods: A literature review synthesized preclinical and clinical data on targeted therapy responses, and a retrospective analysis evaluated INOVA Schar Cancer patients in a Molecular Tumor Board database who received targeted therapy. Results: Published data show variable responses across non-V600 classes, with one partial remission and two stable disease cases in the INOVA cohort. Conclusions: Targeted therapy evidence remains evolving, supporting further mechanism-based studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-non-v600-mutations-in-braf-a-single-institution-retrospective-analysis-and-review-of-the-literature/338261/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-non-v600-mutations-in-braf-a-single-institution-retrospective-analysis-and-review-of-the-literature/338261.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are non-V600 BRAF mutations clinically challenging compared with V600 mutations?","Question",{"text":112,"@type":113},"They represent about 10% of BRAF mutations and lack a standard targeted treatment regimen, unlike established V600-focused paradigms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methods were used to evaluate targeted therapies for non-V600 mutations?",{"text":117,"@type":113},"The study combined a literature review of preclinical and clinical reports with a retrospective analysis of INOVA Schar Cancer patients receiving targeted therapy and assessed time to next treatment and best response.",{"name":119,"@type":110,"acceptedAnswer":120},"What response outcomes were observed in the INOVA cohort?",{"text":121,"@type":113},"One patient achieved partial remission and two patients achieved stable disease, reflecting promising but limited outcomes consistent with variable published response rates across mutation classes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338261,1792112259,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Drugs in R&D (2024) 24:395–403  \n[https://doi.org/10.1007/s40268-024-00475-5](https://doi.org/10.1007/s40268-024-00475-5)  \nTargeting Non‑V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature  \nHirra A. Chaudhary1,2 · Timothy L. Cannon1 · Arthur Winer1  \nAccepted: 23 June 2024 / Published online: 23 August 2024 © The Author(s) 2024  \nAbstract  \nBackground and Objective While successful treatment paradigms for BRAF V600 mutations have been developed, 10% of BRAF mutations are not at V600 and lack a standard treatment regimen. This study summarizes the current body of knowledge on the treatment of non-V600 mutations and reports a single institution experience.  \nMethods We conducted a literature review to summarize relevant preclinical and clinical published data on the response of non-V600 mutations to targeted therapies. We performed a retrospective analysis of INOVA Schar Cancer patients registered in our Molecular Tumor Board database with non-V600 BRAF mutations who were recipients of targeted therapy and assessed their time to next treatment and best response.  \nResults Published preclinical and clinical data have demonstrated limiting results in the response of non-V600 mutated cancers to targeted therapies. Response rates were variable for the major classes of BRAF mutations including class II and class III mutations as well as, BRAF fusions. Data collected from our INOVA cohort offered promising results with one patient achieving partial remission and two patients achieving stable disease.  \nConclusions This article reflects the current understanding of targeted therapies in non-V600 mutations. Further large-scale studies separating BRAF mutations based on their mechanism of activation will expand our understanding.  \n* Hirra A. Chaudhary [fjt9gc@virginia.edu](fjt9gc@virginia.edu)  \n1 INOVA, Schar Cancer Institute, Fairfax, VA, USA  \n2 UVA School of Medicine, INOVA Fairfax Medical Campus, Fairfax, VA, USA  \n1 Introduction  \nThe serine-threonine kinase BRAF plays a critical role in the MAPK pathway promoting cell growth and survival. BRAFoncogenic mutations result in constitutive activation of this pathway and have been implicated in multiple cancer types, including melanoma, colorectal cancer, and lung cancer. Of all solid tumors, 7–15% are found to have these mutations with a greater frequency in certain disease types such as melanoma. The most common BRAF variant is the V600E point mutation, which comprises 90% of all pathogenic BRAF mutations in cancer [1, 2] . While BRAF V600E-specific targeted monotherapies, such as vemurafenib, resulted in improved progression-free survival and overall survival in treating BRAF V600 mutated cancers, subsequent studies showed further improvement using combination therapy with the addition of a MEK inhibitor [3, 4] . Targeted therapies using combinations of BRAF V600 and MEK inhibitors have improved outcomes across tumor types, which has led to the US Food and Drug Administration pan-tumor approval for dabrafenib and trametinib in all BRAF V600E mutated solid tumors [5] .  \nWhile non-V600 mutations make up 10% of all BRAF mutated cancers, they lack a standard targeted therapy paradigm. Current class I monomer selective BRAF inhibitors inhibit mutant BRAF V600E proteins, which signal as monomers instead of wild-type BRAF that signals as a dimer [6] . Non-V600 mutations are often subdivided into the remaining classes based on their mechanism of activation and are generally categorized as class II, class III, and fusions (Fig. 1) . Class II mutations are constitutively active dimers that are RAS independent with intermediate to high kinase activity. These mutations are primarily found in the activating site or P-loop segment of BRAF, such as K601 and L597 or G464 and G469, respectively. Class III mutations have lowlevel kinase activity and require upstream RAS signaling for dimerization. These aberrations often coexist with other MAPK pathway ","cbCaitOzZG9jNoeq","https://ap.wps.com/l/cbCaitOzZG9jNoeq","pdf",853568,"English","# Abstract\n## Background and Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n## BRAF and MAPK pathway role\n## Non-V600 mutation classes\n## Class II and Class III mutations\n## BRAF fusions\n# Review of Literature\n## Clinical trials and published evidence\n## Literature search and collected response data","[{\"question\":\"Why are non-V600 BRAF mutations clinically challenging compared with V600 mutations?\",\"answer\":\"They represent about 10% of BRAF mutations and lack a standard targeted treatment regimen, unlike established V600-focused paradigms.\"},{\"question\":\"What methods were used to evaluate targeted therapies for non-V600 mutations?\",\"answer\":\"The study combined a literature review of preclinical and clinical reports with a retrospective analysis of INOVA Schar Cancer patients receiving targeted therapy and assessed time to next treatment and best response.\"},{\"question\":\"What response outcomes were observed in the INOVA cohort?\",\"answer\":\"One patient achieved partial remission and two patients achieved stable disease, reflecting promising but limited outcomes consistent with variable published response rates across mutation classes.\"}]","Targeting Non-V600 Mutations in BRAF - A Single Institution Retrospective Analysis and Review of the Literature | PDF",1790022813,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2aec43fc8afe1d901a1740674198b67e.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/318979ad97e2c20105754c02803bab96.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b36f98ad4fc9e1b859eb2d8dbfcc924.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a233cf0ef5361b1906207b52c11f0a2e.webp",980,1301]